Repaglinide Teva 0.5 mg tablets

Repaglinide Teva is a medicine that contains the active substance repaglinide. It is available as round tablets (blue: 0.5 mg; yellow: 1 mg; peach: 2 mg).
Repaglinide Teva is a ?generic medicine?. This means that Repaglinide Teva is similar to a ?reference medicine? already authorised in the European Union (EU) called NovoNorm. For more information on generic medicines, see the question-and-answer document here.

Repaglinide Teva is used in patients who have type 2 diabetes (non-insulin-dependent diabetes). It is used together with diet and exercise to lower blood glucose (sugar) levels in patients whose hyperglycaemia (high blood glucose levels) cannot be controlled by diet, weight reduction and exercise. Repaglinide Teva may also be used with metformin (another anti-diabetes medicine) in type 2 diabetes patients whose blood glucose levels are not satisfactorily controlled on metformin alone.

Repaglinide Teva is taken before meals, normally up to 15 minutes before each main meal. The dose is adjusted to give the best control. A doctor should regularly test the patient?s blood glucose to find the lowest effective dose. Repaglinide Teva can also be used for type 2 diabetes patients whose blood glucose levels are usually controlled well on diet, but are experiencing temporary loss of blood glucose control.
The recommended starting dose is 0.5 mg. This dose may need to be increased after one or two weeks. If patients are transferred from another anti-diabetes medicine, the recommended starting dose is 1 mg.

Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. Repaglinide Teva helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes.

Because Repaglinide Teva is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine (this means that the two medicines produce the same levels of the active substance in the body).

Because Repaglinide Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.

Because Repaglinide Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.

The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Repaglinide Teva has been shown to have comparable quality and to be bioequivalent to NovoNorm. Therefore, the CHMP?s view was that, as for NovoNorm, the benefit outweighs the identified risk. The Committee recommended that Repaglinide Teva be given marketing authorisation.